SynthesisAndrology2026
Boosting Male Fertility: The Impact of Gonadotropin Therapy on Hypogonadotropic Hypogonadism-A Systematic Review and Meta-Analysis.
Synthesis in Andrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMale hypogonadotropic hypogonadism typically presents with azoospermia and is one of the few causes of infertility amenable to a medical intervention. Gonadotropin therapy offers a chance to restore spermatogenesis and fertility in these individuals. Therefore, this study aims to determine the efficacy of gonadotropins in inducing spermatogenesis and achieving pregnancies in males with hypogonadotropic hypogonadism and azoospermia. Additionally, the time needed to induce spermatogenesis and pregnancy, and potential predictors associated with better outcomes, were evaluated.
methodsA systematic literature search was conducted in the Medline, Embase, and Cochrane databases till May 16, 2025. Clinical studies, including randomized control trials, cohort studies, and case-control studies, using gonadotropins as a treatment for hypogonadotropic hypogonadism and assessing sperm induction or pregnancy outcomes, were eligible for inclusion. Primary outcomes included sperm parameters (appearance, concentration, motility, morphology, time needed to induce spermatogenesis) and pregnancy outcomes (pregnancy rate, proportion of naturally achieved pregnancies, proportion of live births, and time to conception). The methodological quality and risk of bias were assessed using the Effective Public Health Practice Project quality assessment tool for quantitative studies, and showed that most included studies were of poor methodological quality.
resultsA total of 50 studies were included from 2351 identified articles, treating 1583 male patients with hypogonadotropic hypogonadism and azoospermia. The pooled success rate of spermatogenesis induction was 74% (95% confidence interval: 66%-82%), with a mean time to spermatogenesis of 11.8 months. The overall pregnancy rate among couples with a child wish was 52% (95% confidence interval: 42%-62%), with a mean time to pregnancy from the start of treatment of 19 months. Mean post-treatment sperm concentration was 9.8 million/mL (95% confidence interval 8.6-11.0), and spontaneous pregnancies also occurred with suboptimal sperm parameters. Gonadotropin dual therapy was more effective than human chorionic gonadotropin monotherapy.
conclusionGonadotropin therapy, particularly combined gonadotropin treatment, is effective in restoring spermatogenesis and achieving pregnancy in men with hypogonadotropic hypogonadism. While sperm quality often remains below normal thresholds, natural conception is frequently achieved. These findings support the use of combined gonadotropin therapy as the first-line approach for fertility induction in this population.
trial registrationThis review was registered on PROSPERO under the registration number CRD4202232149. A review protocol was not previously published.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.